CClinicalTrials.gg
CompletedNCT05520424Updated Apr 3, 2024

An Exploratory Investigation of a Supplement to Promote Brain Health

An interventional study of The Daily Supplement in Memory Deficits, Cognitive Change and Stress, sponsored by Parable. Completed at 1 site in United States. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Parable · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
All
01

Study summary

Providing a combination of synergistic dietary supplements, such as vitamins B6, B12, and folate, as well as curcumin, lemon balm, and American ginseng is hypothesized to promote brain health and aid with brain fog, mental clarity, ability to handle stress, mood, focus, and productivity, as well as promote overall well-being.

02

Conditions studied

  • Memory Deficits
  • Cognitive Change
  • Stress

Browse trials for

Keywords

  • Focus
  • Memory
  • Attention
  • Stress
03

In context

Memory Disorders

260 studies on the registry are indexed under Memory Disorders; 60 are open to participants now.

This study's enrollment of 40 is below the median of 73 across 207 interventional studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

This is the only study on the registry with Parable as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • In good general health with no major chronic conditions (e.g., diabetes, coronary heart disease, etc.)

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breastfeeding
  • Anyone currently taking other supplements
  • Anyone with a known allergic reaction
  • Previous head trauma
  • Anyone with chronic diseases such as diabetes, coronary heart disease, or cancer.
  • Any psychological, mental, or neurodevelopmental disorders
  • Consumes nicotine or marijuana in any form
  • Previous or current alcohol addiction
  • Consume more than 10 drinks per week
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    The Daily Supplement

    Participants will use test product daily, and complete Biomarker assessments (at 1st dose, Day 7, Day 31), as well as surveys (at 1st dose, Day 7, Day 31), and Cognitive battery Assessments (at 1st dose, Day 7, Day 31).

    Dietary Supplement: The Daily Supplement

Interventions

  • Dietary supplementThe Daily Supplement

    The ingredient list of the product includes the following: 400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)

06

What researchers measure

Primary outcomes

  1. Perceived changes in mental health symptoms as measured by Questionnaires

    Questionnaires measure perceived changes in mental health symptoms (e.g., anxiety levels, mental clarity) and stress management on a scale of 0 (low levels of mental health symptoms) to 10 (very high levels of mental health symptoms)

    Time frame: 31 days

  2. Perceived changes in stress management as measured by Questionnaires

    Questionnaires measure perceived changes in stress management on a scale of 0 (poor ability to manage stress) to 10 (excellent ability to manage stress)

    Time frame: 31 days

Secondary outcomes

  1. Changes in Cognitive Functioning

    Cognitive battery questionnaires measure executive functioning, long term memory, working memory, and attention.

    Time frame: 31 days

Other outcomes

  1. Changes in plasma/serum biomarkers associated with brain health

    Biomarkers collected via. blood sample sent to a third party lab. The biomarkers of interest for this trial include hs-CRP, HbA1c, homocysteine, and IL-6.

    Time frame: 31 days

07

Study locations

1 site
  • Citruslabs
    Santa Monica, California 90404, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05520424
Lead sponsor
Parable
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Jun 15, 2022
Primary completion
Oct 30, 2022
Completion
Oct 30, 2022
Last update
Apr 3, 2024

Study contacts

Christopher Hill, PhD
principal investigator · Citruslabs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion